Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T17:10:48.237Z.
Calculation as of: 2026-10-06T17:10:48.237Z.
Quote observation: 2026-10-06T17:08:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d88ebff11657cb0645ea93f74423bc241bf41286751ec96f31399ab1bd3406dc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-05-14.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$7.97M
EV/Sales Ratio
N/A
TTM Avg
2618.99x
3Y Avg
2618.99x
5Y Avg
2618.99x
Market Cap
$7.95M
EV/Sales Ratio
N/A
TTM Avg
1162726.42x
3Y Avg
640219.29x
5Y Avg
640219.29x
Market Cap
$8.25M
EV/Sales Ratio
N/A
TTM Avg
802.02x
3Y Avg
903.36x
5Y Avg
873.57x
Market Cap
$8.50M
EV/Sales Ratio
0.76x
TTM Avg
0.33x
3Y Avg
0.31x
5Y Avg
0.34x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | $7.93M | N/A | N/A | N/A | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.97M | N/A | 2618.99x | 2618.99x | 2618.99x |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.96M | N/A | N/A | N/A | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.95M | N/A | 1162726.42x | 640219.29x | 640219.29x |
| HeartSciences Inc. (HSCS)vs › | $8.25M | N/A | 802.02x | 903.36x | 873.57x |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.66M | N/A | N/A | N/A | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.50M | 0.76x | 0.33x | 0.31x | 0.34x |
| DataMEDS AI, Inc. (MEDS)vs › | $8.53M | 4.82x | 2.16x | 2.16x | 2.16x |
| Skye Bioscience, Inc. (SKYE)vs › | $7.40M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 0.00x | 0.29x | 0.29x | 1.64x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2024-05-14 | 0.69x |
| 2024-04-16 | 0.43x |
| 2024-04-15 | 0.75x |
| 2024-04-11 | 0.75x |
| 2024-04-10 | 2.68x |
| 2024-04-09 | 1.65x |
| 2024-04-08 | 2.68x |
| 2024-04-05 | 3.32x |
| 2024-04-04 | 2.48x |
| 2024-04-03 | 5.69x |
| 2024-04-02 | 5.24x |
| 2024-04-01 | 3.64x |
| 2024-03-28 | 5.82x |
| 2024-03-27 | 1.84x |
| 2024-03-08 | 2.25x |
| 2024-03-07 | 4.35x |
| 2024-03-06 | 9.86x |
| 2024-03-05 | 9.07x |
| 2024-03-04 | 10.58x |
| 2024-03-01 | 7.96x |
| 2024-02-29 | 10.97x |
| 2024-02-28 | 2.71x |
| 2024-02-27 | 3.16x |
| 2024-02-26 | 2.38x |
| 2024-02-23 | 2.97x |
| 2024-02-08 | 0.61x |
| 2024-02-06 | 3.69x |
